

Press Release

Notice Regarding Issuance of Unsecured Bonds

TOKYO, August 25, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) successfully priced a dual-tranche of series 3rd and 4th JPY denominated unsecured bonds (“the Bonds”) as below. The issuance of the Bonds is intended to partially repay and redeem short-term loans from financial institutions and commercial papers to finance the acquisition of IVERIC bio, Inc. which was completed in July 2023.

1. Name of the Bonds	Astellas Series 3 Unsecured Bonds (Subject to a limited inter-bond pari passu clause)	Astellas Series 4 Unsecured Bonds (Subject to a limited inter-bond pari passu clause)
2. Maturity	3 years	5 years
3. Issue amount	JPY 100 billion	JPY100 billion
4. Denomination of each bond	JPY 100 million	
5. Interest rate	0.320% per annum	0.519% per annum
6. Issue price	100.00% of the principal amount	
7. Redemption price	100.00% of the principal amount	
8. Redemption method	Bullet Maturity Date: August 31, 2026	Bullet Maturity Date: August 31, 2028
9. Interest payment dates	The last day of February and August for each year (Initial interest payment date: February 29, 2024)	
10. Method of offering	Public offering	
11. Pricing date	August 25, 2023	
12. Issue date	August 31, 2023	
13. Collateral and guarantees	The Bonds are not secured by any collateral or guarantees, and no assets have been retained specifically to secure them	
14. Financial clauses	The Bonds carry a negative pledge clause (limited inter-bond pari passu clause)	

15. Lead managers	Mizuho Securities Co., Ltd., Nomura Securities Co., Ltd., Mitsubishi UFJ Morgan Stanley Securities Co., Ltd., Daiwa Securities Co. Ltd., SMBC Nikko Securities Inc. and Goldman Sachs Japan Co., Ltd.
16. Fiscal agent	Sumitomo Mitsui Banking Corporation
17. Bond rating	AA (Rating and Investment Information, Inc.)

For more information about the acquisition of IVERIC bio, Inc., please see [the press release on “Astellas Enters into Definitive Agreement to Acquire Iveric Bio” issued on May 1, 2023](#) and [the press release on “Astellas Completes Acquisition of Iveric Bio” issued on July 12, 2023](#).

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+[®] healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at <https://www.astellas.com/en>.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

This press release is not an offer of securities for sale in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws of the United States, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws of the United States.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
+81-3-3244-3201